Dossier assessment
Empagliflozin/linagliptin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Empagliflozin/linagliptin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Empagliflozin/linagliptin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
Adults with type 2 diabetes mellitus when diet and exercise plus at least 2 blood-glucose lowering drugs (except insulin, here metformin/sulphonylurea and empagliflozin/linagliptin) do not provide adequate glycaemic control
Added benefit not proven due to a lack of suitable study data
Additional information
Federal Joint Committee (G-BA)
2019-11-22 A G-BA decision was published.
Project details
- Project no.
- A19-49
- Commission
- Commission awarded on 29.05.2019 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Digestion, metabolism and hormones
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.